SEC Comment Letter 0000000000-26-005827 to Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: June 10, 2026 · CIK: 0001645460 · Accession: 0000000000-26-005827
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296456
Letter
June 10, 2026 Shao-Lee Lin President and Chief Executive Officer Cue Biopharma, Inc. 40 Guest Street Boston, Massachusetts 02135 Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed June 3, 2026 File No. 333-296456 Dear Shao-Lee Lin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Courtney M.W. Tygesson
Show Raw Text
June 10, 2026 Shao-Lee Lin President and Chief Executive Officer Cue Biopharma, Inc. 40 Guest Street Boston, Massachusetts 02135 Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed June 3, 2026 File No. 333-296456 Dear Shao-Lee Lin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Courtney M.W. Tygesson